ArticleExpert opinion on drug discovery2009
Advances in Nuclear Magnetic Resonance for Drug Discovery.
Article in Expert opinion on drug discovery, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Exploring β-catenin and TCF4 interaction in complex environments by means of novel biosensing platform focal molography.PloS one · 2025Article
- In-vivo and in-silico studies revealed the molecular mechanisms ofIn silico pharmacology · 2023Article
- Optimized Inhibitors of MDM2 via an Attempted Protein-Templated Reductive Amination.ChemMedChem · 2020Article
- A fluorinated indole-based MDM2 antagonist selectively inhibits the growth of p53The FEBS journal · 2019Article
- Article
- NMRmix: A Tool for the Optimization of Compound Mixtures in 1D (1)H NMR Ligand Affinity Screens.Journal of proteome research · 2016Article
- Statistical removal of background signals from high-throughput (1)H NMR line-broadening ligand-affinity screens.Journal of biomolecular NMR · 2015Article
- Quantitating metabolites in protein precipitated serum using NMR spectroscopy.Analytical chemistry · 2014Article
- Virtual Screening Analysis and In-vitro Xanthine Oxidase Inhibitory Activity of Some Commercially Available Flavonoids.Iranian journal of pharmaceutical research : IJPR · 2013Article
- A unified NMR strategy for high-throughput determination of backbone fold of small proteins.Journal of structural and functional genomics · 2012Article
- Challenges and opportunities in absorption, distribution, metabolism, and excretion studies of therapeutic biologics.The AAPS journal · 2012Review
- The applicability of molecular descriptors for designing an electrospray ionization mass spectrometry compatible library for drug discovery.Combinatorial chemistry & high throughput screening · 2012Article
- Application of NMR and molecular docking in structure-based drug discovery.Topics in current chemistry · 2012Review
- An inexpensive high-throughput nuclear magnetic resonance tube cleaning apparatus.Analytical biochemistry · 2011Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
backgroundDrug discovery is a complex and unpredictable endeavor with a high failure rate. Current trends in the pharmaceutical industry have exasperated these challenges and are contributing to the dramatic decline in productivity observed over the last decade. The industrialization of science by forcing the drug discovery process to adhere to assembly-line protocols is imposing unnecessary restrictions, such as short project time-lines. Recent advances in nuclear magnetic resonance are responding to these self-imposed limitations and are providing opportunities to increase the success rate of drug discovery. OBJECTIVE/
methodA review of recent advancements in NMR technology that have the potential of significantly impacting and benefiting the drug discovery process will be presented. These include fast NMR data collection protocols and high-throughput protein structure determination, rapid protein-ligand co-structure determination, lead discovery using fragment-based NMR affinity screens, NMR metabolomics to monitor in vivo efficacy and toxicity for lead compounds, and the identification of new therapeutic targets through the functional annotation of proteins by FAST-NMR.
conclusionNMR is a critical component of the drug discovery process, where the versatility of the technique enables it to continually expand and evolve its role. NMR is expected to maintain this growth over the next decade with advancements in automation, speed of structure calculation, in-cell imaging techniques, and the expansion of NMR amenable targets.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.